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Background.—Although triptans are widely used in the acute management of migraine, there is uncertainty around the
comparative efficacy of triptans among each other and vs non-triptan migraine treatments. We conducted systematic reviews
and network meta-analyses to compare the relative efficacy of triptans (alone or in combination with other drugs) for acute
treatment of migraines compared with other triptan agents, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic
acid (ASA), acetaminophen, ergots, opioids, or anti-emetics.
Methods.—The Cochrane Library, MEDLINE, and EMBASE were searched for randomized controlled trials that com-
pared triptans (alone or in combination with other drugs) with placebo-controlled or active migraine treatments. Study
selection, data extraction, and quality assessment were completed independently by multiple reviewers. Outcome data were
combined and analyzed using a Bayesian network meta-analysis. For each outcome, odds ratios, relative risks, and absolute
probability of response were calculated.
Results.—A total of 133 randomized controlled trials met the inclusion criteria. Standard dose triptans relieved headaches
within 2 hours in 42 to 76% of patients, and 2-hour sustained freedom from pain was achieved for 18 to 50% of patients.
Standard dose triptans provided sustained headache relief at 24 hours in 29 to 50% of patients, and sustained freedom from pain
in 18 to 33% of patients. Use of rescue medications ranged from 20 to 34%. For 2-hour headache relief, standard dose triptan
achieved better outcomes (42 to 76% response) than ergots (38%); equal or better outcomes than NSAIDs, ASA, and
acetaminophen (46 to 52%); and equal or slightly worse outcomes than combination therapy (62 to 80%). Among individual
triptans, sumatriptan subcutaneous injection, rizatriptan ODT, zolmitriptan ODT, and eletriptan tablets were associated with
the most favorable outcomes.
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Interpretation/Conclusions.—Triptans are effective for migraine relief. Standard dose triptans are associated with better
outcomes than ergots, and most triptans are associated with equal or better outcomes compared with NSAIDs, ASA, and
acetaminophen. Use of triptans in combination with ASA or acetaminophen, or using alternative modes of administration such
as injectables, may be associated with slightly better outcomes than standard dose triptan tablets.
Key words: triptan, efficacy, benefit, migraine, systematic review, network meta-analysis
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Migraine is a common and potentially disabling
neurological condition characterized by recurrent
moderate to severe pain generally occurring on one
side of the head. Globally, it is estimated that over
10 to 15 percent of people suffer from migraines.1
The condition causes short- and long-term disability,
reduces quality of life, and often impacts work pro-
ductivity, social relationships, and family life.2-4
The acute management of migraines includes
the use of non-steroidal anti-inflammatory drugs
(NSAIDs), acetaminophen, ergots, opioids, and
triptans. For many patients with moderate to
severe migraine, triptans are considered the first-line
therapy. There are now seven triptans (almotriptan,
eletriptan, frovatriptan, naratriptan, rizatriptan,
sumatriptan, and zolmitriptan) available in Canada.
The relative efficacy of each triptan among each other
is uncertain since the majority of triptan studies
have been placebo controlled. Further, while other
reviews3-10 have attempted to examine the relative
efficacy of triptans among each other and vs non-
triptan migraine treatments, these studies have not
considered multiple routes of administration (tablets,
oral disintegrating tablets, injection, nasal spray, rectal
suppositories), combination triptan therapy, or dose.
Therefore, as part of a larger initiative by the
Ontario Drug Policy Research Network to evaluate
triptans for the acute treatment of migraine in adults
and provide recommendations for funding changes of
these drugs in Ontario (http://odprn.ca/drug-class-
review/completed-reviews/triptans/), we conducted a
systematic review and network meta-analysis to
address the following research question: What is
the evidence for the efficacy, effectiveness, and safety
of triptans (alone or in combination with other
drugs) for acute treatment of migraines compared
with: other triptan agents, NSAIDs, acetylsalicylic
acid (ASA), acetaminophen, ergots, opioids, or
anti-emetics?
METHODS
Data Sources and Searches.—Published random-
ized controlled trials (RCTs) were identified using
electronic search strategies developed and tested by
an experienced medical information specialist in
consultation with the review team. Using the OVID
platform, we searched Ovid MEDLINE®, Ovid
MEDLINE® In-Process & Other Non-Indexed
Citations, and Embase Classic + Embase to identify
English-language RCTs published from inception to
October 6, 2013. Using the Cochrane Library on
Wiley, the Cochrane Database of Systematic Reviews
and CENTRAL were also searched. Strategies
utilized a combination of controlled vocabulary (eg,
migraine disorders, tryptamines) and keywords (eg,
triptans, rizatriptan, sumatriptan). Vocabulary and
syntax were adjusted across databases. Additional
references were also sought through hand searching
the bibliographies of relevant articles. Gray literature
was searched using Google Scholar and the clinical
trial sites listed in CADTH’s Grey Matters (http://
cadth.ca/resources/grey-matters). Complete details of
the electronic search strategy, including any limits
used, are reported in Appendix S1.
Study Selection.—The protocol was peer reviewed
and published online prior to the start of the review.
Studies were eligible for inclusion in the systematic
review if they satisfied the population, intervention,
comparator, and outcome (PICO) statement, includ-
ing the study designs of interest outlined in our
protocol.
The population of interest were adults 18 years
and older with migraine specified by the International
HeadacheSociety (IHS1988;IHS2004,IHS ICDH-2).
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Studies which included patients with cluster, tension
or other headaches, chronic or recurrent migraines
who are not experiencing an acute episode were not
included. Active and placebo-controlled RCTs were
selected for inclusion if theywere published inEnglish
and included at least one triptan under review. The
following triptans were included in the review:
almotriptan, eletriptan, frovatriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan. Triptans
were allowed to be used alone or in combination with
other drugs. All routes of administration (tablets,
oral disintegrating tablets, injection, nasal spray, and
rectal suppositories) and all doses (any frequency or
strength) were included. Doses are classified accord-
ing to Table 1.Allowable comparator groups include:
placebo; other triptans used either alone or in combi-
nation with other acute migraine therapies; or other
acute pharmacologic migraine treatment options (eg,
NSAIDs, ASA, acetaminophen, ergots, opioids, anti-
emetics). Numerous outcomes were considered and
results are reported elsewhere: http://odprn.ca/drug-
class-review/completed-reviews/triptans/; however,
the focus of this publication are: headache relief at 2
hours; freedom from pain at 2 hours; sustained head-
ache response at 24 hours; sustained freedom from
pain at 24 hours; and use of rescue medication. In
general, headache relief was defined as a reduction in
headache intensity frommoderate or severe tomild or
none at 2 or 24 hours,whereas freedom from pain was
defined as the percentage of patients pain-free at 2 and
24 hours.
Screening, Data Extraction, and Quality
Assessment.—In the first phase of screening, the titles
and abstracts of all identified citations were screened
by two independent reviewers (MM, JP). In the
second phase of screening, full manuscripts were
retrieved and screened by two independent reviewers
on the basis of our predefined patient population,
intervention, comparison, outcomes, and study design
of interest. We only included RCTs/crossovers that
reported data for the first attack.Disagreements were
resolved through discussion or through adjudication
by a third reviewer (SK). For each included study, one
of four reviewers independently (MM, JP, SCH,AK)
extracted the data on characteristics of trial partici-
pants, study characteristics, and details on each study
arm/pharmacological intervention, including but not
limited to: dose, frequency, route of administration,
co-medication/prophylaxis, and results of the clinical
safety and efficacy outcomes for the overall study
population and the a priori subgroups identified. All
extracted data were checked for accuracy by another
reviewer. Any disagreements in the assessment of
these data were resolved through discussion until
consensus was reached.
Quality assessment of RCTs was performed inde-
pendently by four reviewers (MM, JP, SCH, AK)
using a standardized table based on major items from
the Cochrane Risk of Bias Tool.11 The trial selection
process is presented in a flowchart based on the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)12,13 statement (Fig. 1).
Table 1.—Dose Categorization for a Migraine Attack (and Number of RCTs/Number of Patients for 2-Hour Relief)†
Low dose
(Half)
Standard dose
(Common)
High dose
(Double)
Eletriptan 20 mg (3 RCTs/514 patients) 40 mg (13 RCTs/3143 patients) 80 mg (10 RCTs/2042 patients)
Sumatriptan 25 mg (4 RCTs/850 patients) 50 mg (23 RCTs/5870 patients) 100 mg (23 RCTs/5210 patients)
Rizatriptan 5 mg (3 RCTs/752 patients) 10 mg (11 RCTs/2676 patients) 20 mg (1 RCT/82 patients)
Frovatriptan – 2.5 mg (5 RCTs/1840 patients) 5 mg (2 RCTs/338 patients)
Almotriptan 6.25 mg (2 RCTs/527 patients) 12.5 mg (7 RCTs/2120 patients) 25 mg (2 RCTs/352 patients)
Zolmitriptan 1.25 mg (1 RCT/52 patients) 2.5 mg (10 RCTs/3491 patients) 5 mg (6 RCTs/2084 patients)
Naratriptan – 2.5 mg (3 RCTs/512 patients) 5 mg (No data)
†Numbers for other outcomes are reported in Appendix S6.
– = no low dose available/relevant for this medication.
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Data Synthesis and Analysis.—We performed a
Bayesian network meta-analysis.A Bayesian network
meta-analysis requires two main elements: a likeli-
hood function derived from a model that specifies
the relation between the unknown parameters and
the observed data, and prior distributions for the
unknown parameters.14 A prior distribution of a
parameter represents the uncertainty of parameter
before the data are examined.14,15 The prior chosen
may be informative or “vague” where the latter is
thought to let the data drive the analysis. Multiplying
the prior and the likelihood function leads to the
posterior distribution of the parameter, which is used
to carry out all inferences in a Bayesian analysis.14,15
Methods for Bayesian network meta-analyses allow
analysis of both placebo and active comparison
studies simultaneously.14 Both direct and indirect
pieces of evidence are combined. The results from
indirect evidence combined with the direct evidence
may strengthen the assessment between treatments
evaluated using Bayesian network meta-analysis.
Bayesian network meta-analyses were conducted
usingWinBUGS software version 1.4.3 (MRCBiosta-
tistics Unit, Cambridge, UK). A binomial likelihood
model which accounts for the use of multi-arm trials
was used for the analyses given the datasets provided
Records identified through database
searching
(n = 1694) 
Additional records identified through
other sources
(n = 78) 
Records after duplicates were removed
(n = 1142)
Records screened
(n = 1142)
Records excluded
(n = 730)
Full-text articles assessed for
eligibility
(n = 412)
Full-text articles excluded,
with reasons
(n = 210)
Abstract only = 30
Duplicate = 34
Population = 10
Non-English = 9
Study design = 108
Intervention = 15
Could not locate = 4
Studies included in
qualitative synthesis
(n = 202) 
Studies included in
quantitative synthesis
(meta-analysis)
(n = 202)
(n = 133 with single attack)
Fig 1.—PRISMA diagram.
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were dichotomous outcomes and included multi-arm
trials.14 Bayesian network meta-analyses were con-
ducted for the following outcomes: headache relief
within 2 hours; freedom from pain at 2 hours; sus-
tained headache response at 24 hours; sustained
freedom from pain at 24 hours; and use of rescue
medication. Placebo was chosen as the reference
group or index node in the model. Both random-
effects network meta-analyses using informative
priors and fixed-effects analyses were conducted;14,15
assessment of model fit and choice of model was
based on assessment of the deviance information cri-
terion (DIC) between study standard deviation and
comparison of residual deviance to number of uncon-
strained data points.16,17
Point estimates and 95% credible intervals for
odds ratios (OR) were derived using Markov Chain
Monte Carlo methods for all nodes in analysis. Risk
ratios and absolute risk for an outcome of interest
were estimated based on the ORs and the mean pro-
portion of patients who experience the outcome in
the placebo arms among included studies. Vague
priors, such as N(0, 1002), were assigned for basic
parameters throughout17 and informative priors for
the variance parameter based on evidence on the
extent of heterogeneity observed in previous meta-
analyses, as described in Turner et al.15 To ensure con-
vergence was reached, trace plots and the Brooks–
Gelman–Rubin statistic were assessed.15,18 Three
chains were fit inWinBUGS for each analysis, with at
least 20,000 iterations, and a burn-in of at least 20,000
iterations.18,19
We also qualitatively compared the results from
our network meta-analysis with direct pairwise esti-
mates.We formally assessed inconsistency by compar-
ing the deviance between study variance and DIC
statistics in fitted consistency and inconsistency
models.20 We also plotted the posterior mean devi-
ance of the individual data points in the inconsistency
model against their posterior mean deviance in the
consistency model to identify any loops where incon-
sistency is present.20 We also conducted a sensitivity
analysis adjusting for control group response rate to
address heterogeneity among included studies and
generated a box plot to illustrate differences among
included studies.
RESULTS
Search Results.—The initial literature search
returned 1694 database abstracts and 78 gray
literature documents (Fig. 1). After duplicates were
removed, 1142 remained to be assessed for inclusion
and 730 were excluded. Of the 412 full-text articles
reviewed, 202 full-text publications were included
after applying the PICO criteria. Of these, 69 were
excluded from analysis as they did not present single
migraine attack data. A total of 133 publications
reported single migraine attack data in 133 unique
RCTs. A complete list of included and excluded
studies is available in Appendix S2.
Characteristics of Included Studies.—A detailed
list of included studies, patients and study character-
istics is provided in the technical report.All included
studies were published between 1991 and 2012. Most
were large, multicenter studies conducted in a variety
of countries worldwide, and often across many differ-
ent countries. The number of randomized patients
was often bigger than the number of participants
included in the effect estimates for outcomes in each
trial, due to the fact that most trials reported modified
intention to treat outcome populations, ie, based on
recruited patients who subsequently experienced
a migraine event. The trials all recruited migraine
sufferers who met the International Classification
of Headache Disorders (ICHD) for migraine
headaches,21-24 or used inclusion criteria with suffi-
cient comparability to the ICHD criteria. All
studies generally included patients affected with
migraine with or without aura, and a small number
also included some patients with menstrual
migraine.25-27 Four RCTs reported solely onmenstrual
migraine in female participants.28-31 All participants
self-administered their study medications. Trial par-
ticipants were generally between the ages of 18 and
65, with an average age of approximately 40.Very few
trials included participants older than 65, and trials of
children and adolescents were excluded by the PICO
statement. Trial participants were predominantly
female. In 133 studies reporting first attack data, the
mean percent of females included was over 80%.
Patients included in studies were both treatment
naïve and experienced. In general, a high proportion
of studies included participants with at least one
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previous treatment failure with a triptan. The risk of
bias assessment for each study is available upon
request.
Headache Relief at 2 Hours.—The evidence
network for headache relief at 2 hours included 96
studies and a total of 56,180 participants (Table 2).
Overall, 45 different treatments were considered, pro-
viding for 287 comparisons.There is some evidence of
inconsistency in the network (Appendix S3). Stan-
dard dose (SD) triptans relieved headaches within 2
hours in 42 to 76% of patients, compared with 27%
for placebo. Sumatriptan subcutaneous injection
(76%), rizatriptan ODT (69%), zolmitriptan ODT
(66%) had the largest effect on 2-hour headache
relief among monotherapies, whereas ergots (38%),
frovatriptan (42%), naratriptan (46%), and ASA
(46%) were associated with less favorable outcomes.
SD triptans yielded equal or slightly worse outcomes
than triptan combination therapies (62% to 80%).
Detailed results are reported in Table 3 including
credible intervals around point estimates.
Freedom From Pain at 2 Hours.—The evidence
network for freedom from pain at 2 hours included 88
studies and a total of 50,929 participants. Overall, 41
different treatments were considered, involving 236
comparisons. There was no evidence of inconsistency
in the network (Appendix S3). With SD triptans,
only 18 to 50% of patients had freedom from pain
within 2 hours, compared with 11% for placebo.
Rizatriptan ODT (50%), eletriptan tablet (39%),
rizatriptan tablet (37%), sumatriptan subcutaneous
injection (37%), and zolmitriptan ODT (37%) had
the largest effect on 2-hour freedom from pain among
monotherapies, whereas ergots (16%), naratriptan
(18%), NSAIDs (22%), and acetaminophen (22%)
were associated with less favorable outcomes. SD
triptans yielded equal or slightly worse outcomes
than triptan combination therapies (37% to 51%).
Detailed results are reported in Table 3 including
credible intervals around point estimates.
Sustained Headache Relief at 24 Hours.—The evi-
dence network for headache relief at 24 hours
included 29 studies and a total of 22,963 participants.
Overall, 24 different treatments were compared,
involving 102 comparisons. There was no evidence of
inconsistency in the network (Appendix S3). SD
triptans provided sustained headache relief at 24
hours ranging from 29% to 50%, compared with
17% for placebo. Zolmitriptan ODT (50%) and
eletriptan tablet (47%) had the largest effect on 24
hour headache relief among monotherapies, whereas
ergots (8%), acetaminophen (29%),ASA (29%), and
rizatriptan (29%) were associated with less favorable
outcomes. SD triptans yielded equal or slightly worse
outcomes than triptan combination therapies (46% to
50%). Detailed results are reported in Table 3 includ-
ing credible intervals around point estimates.
Sustained Freedom From Pain at 24 Hours.—The
evidence network for freedom from pain at 24 hours
included 42 studies and a total of 27,755 participants.
Overall, 20 different treatments were considered,
involving 115 comparisons. There was no evidence of
inconsistency in the network (Appendix S3). Eight-
een to 33% of patients on SD triptans had sustained
Table 2.—Summary of Patient and Study Characteristics for Each Evidence Network:† Headache Relief at 2 Hours, Freedom
From Pain at 2 Hours, Sustained Headache Relief at 24 Hours, Sustained Freedom From Pain at 24 Hours, and Use of Rescue
Medications
2-hour headache
relief
2-hour freedom
from pain
24-hour sustained
headache relief
24-hour sustained
freedom from pain
Use of rescue
medications
Number of studies 96 88 29 42 88
Number of treatment nodes 45 41 24 20 34
Number of participants 56,180 50,929 22,963 27,775 48,363
Number of comparisons 287 236 102 115 222
Number of 2-arm trials 46 47 13 23 50
Number of multi-arm trials 50 41 16 19 38
†Evidence networks consisted of a large number of nodes, which makes it difficult to illustrate graphically.
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freedom from pain at 24 hours, compared with 10%
for placebo. Eletriptan tablet (33%) and rizatriptan
tablet (24%) had the largest effect on 24-hour
freedom from pain among monotherapies, whereas
acetaminophen (14%), ASA (16%), and naratriptan
(18%) were associated with less favorable outcomes.
SD triptans yielded equal or slightly worse outcomes
than triptan combination therapies (29% to 33%).
Detailed results are reported in Table 3 including
credible intervals around point estimates.
Use of Rescue Medications.—The evidence
network for the use of rescue medication included 88
studies and a total of 48,363 participants. Overall, 34
different treatments were considered, providing for
222 comparisons.There was evidence of inconsistency
in the network (Appendix S3). With SD triptans, the
percent of patients using rescue medications ranged
from 20 to 34%, compared with 52% for placebo.The
NNT in order for one patient to avoid use of rescue
medication ranged from 4 to 6 patients. Eletriptan
tablet (21%) and zolmitriptan tablet (24%) required
the use of the least amount of rescue medications
among monotherapies, whereas NSAIDs (37%),
sumatriptan tablet (34%), and ASA (33%) used the
most. SD triptans yielded equal or slightly worse out-
comes than triptan combination therapies (22%).
Detailed results are reported in Table 3 including
credible intervals around point estimates.
Comparisons Among the SD Triptans.—Figure 2
provides comparisons among the SD triptan tablets.
The gray circle indicates that the triptan identified
in the “row” is associated with better outcomes than
the “column” triptan; the black circle indicates that
the “row” triptan is associated with worse outcome
than the “column” triptan; the blank circle indicates
that there is no difference between the “row” and
“column” triptan; and a missing circle indicates that
the outcome was not available for analysis. In general,
there were more favorable results observed for
eletriptan and rizatriptan (as indicated by the gray
circles in the lower portion of the diagonal in Fig. 2).
Results were less favorable for naratriptan and
frovatriptan. Use of rescue medications was not sig-
nificantly different between the triptans except for
sumatriptan having a significantly favorable result
compared with zolmitriptan. Detailed results are
reported in Appendix S4.
Sensitivity Analyses.—Figure 3 presents a box plot
illustrating control group response rates among treat-
ments included in the network. From Figure 3, it can
be seen that some treatments have lower or higher
control group response rates than other treatments.
We also report findings from a meta-regression analy-
sis adjusting for these differences in control group
response rate. Overall, findings for most treatments
remained unchanged although those with lower
Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Zolmitriptan
Almotriptan
Eletriptan
Frovatriptan
Naratriptan
Rizatriptan
Sumatriptan
Zolmitriptan
Fig 2.—Comparison among the standard dose triptan tablets on the 5 efficacy outcomes: headache relief at 2 hours, freedom from
pain at 2 hours, sustained headache relief at 24 hours, sustained freedom from pain at 24 hours, and use of rescue medications.*
*The 5 contiguous circles correspond, respectively, to the 5 efficacy outcomes: headache relief at 2 hours, freedom from pain at 2
hours, sustained headache relief at 24 hours, sustained freedom from pain at 24 hours, and use of rescue medications. The gray circle
indicates that the “row” triptan is associated with better outcomes compared with “column” triptan; the black circle indicates that
the “row” triptan is worse than the “column” triptan; the blank circle indicates that there is no difference between the “row” and
“column” triptan; and a missing circle indicates that the outcome was not available for analysis.
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control group response rates (eg, SD eletriptan
tablet) became slightly less favorable, albeit still more
favorable than SD triptan tablets (Appendix S5).
DISCUSSION
We found that SD triptans relieved headaches
within 2 hours in 43 to 76% of patients. Freedom from
pain within 2 hours was less common,with about 18 to
50% of patients experiencing freedom from pain
within 2 hours. SD triptans provided sustained head-
ache relief at 24 hours in 29 to 50% of patients, and
sustained freedom from pain at 24 hours in 18 to 33%
of patients.Use of rescue medications among patients
using SD triptans ranged from 20 to 34%. Our find-
ings align with those reported in other systematic
reviews,3-10 although the majority of other reviews
only report estimates of relative effect for SD
triptans.
SD triptans were associated with more favorable
results than ergots for 2- and 24-hour outcomes, and
equal or more favorable results than NSAIDs, ASA,
and acetaminophen for 2-hour outcomes. These find-
ings align with recommendations from the Canadian
Headache Society Guidelines3 where they gave a
strong recommendation for triptans, NSAIDs, ASA,
and acetaminophen but did not recommend ergots
for routine use in the acute management of migraine.
Similarly, the National Institute for Health and Care
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Fig 3.—Comparison of control group response rate among studies for 2-hour response.
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Excellence (NICE) in the UK does not recommend
ergots for the acute treatment of migraine, but rec-
ommends oral triptans, NSAIDs, ASA, and acet-
aminophen for the acute treatment of migraine in
patients who prefer monotherapy.32
We found that combination therapies such as
triptan and ASA or triptan plus acetaminophen, and
certain modes of administration such as rizatriptan
ODT and sumatriptan subcutaneous injection,
were associated with slightly more favorable 2-hour
results compared with SD triptans. However, there is
potential that these findings may be due to system-
atic differences in the patient population and/or
study design; that is, studies assessing efficacy of
combination therapies or certain modes of adminis-
tration may have been more extensively studied in a
patient population that is systematically different,
ie, more severe and/or treatment experienced.
We attempted to adjust for this possible issue by
conducting a meta-regression analysis adjusting for
placebo response rate, a proxy that is often helpful
in identifying patient populations or study designs
that are systematically different (Fig. 3). We found
that findings for combination therapies such as
triptan and ASA or triptan plus acetaminophen
remained stable after adjustment, whereas those
using other modes of administration became slightly
less favorable, albeit still more favorable than SD
triptan tablets. Recent NICE guidance recommends
combination therapy with an oral triptan and ASA
or oral triptan plus acetaminophen, and findings
from both our primary analysis and sensitivity analy-
sis seem to support NICE recommendations.4
Among individual triptans, our analysis suggests
that the majority of triptans, except frovatriptan and
naratriptan, deliver similar pain relief in the acute
management of migraines.However, our findings also
suggest that eletriptan and rizatriptan may provide
better pain relief than some of the other triptans.
This latter finding should be interpreted in light of
a number of caveats. First, findings for eletriptan
became slightly less favorable after we adjusted for
control groups response rate, albeit still more favor-
able than other triptans. Second, both eletriptan and
rizatriptan are only available in tablet forms, whereas
other triptans such as sumatriptan are available in
multiple formulations – which can be advantageous
for patients given mixing of triptans is ill advised.
Finally, we do not consider costs or cost-effectiveness
in this paper. Other triptans such as sumatriptan
are available as less expensive generics, whereas
eletriptan is not yet available as a generic. Our com-
panion pharmacoeconomic report has shown that use
of less costly generic triptans could significantly
reduce total expenditure on triptans.32 However,
providing more open access to triptans will lead to a
significant increase in their use with a high budget
impact. NICE in the UK recommends to start with
the triptan with the lowest acquisition cost initially,
and if this is consistently ineffective, try one or more
expensive alternative triptans.4 Consumer Reports
recommends a similar approach, recommending
sumatriptan initially because it is available as an inex-
pensive generic and offers the widest choice for mode
of delivery.2,33
Studies were not sufficiently powered or of
adequate duration to measure differences in long-
term complications or adverse events. Future
research is needed in assessing the long-term use of
triptans in the acute management of recurrent
migraines.
As with all analyses, there are several limitations
that warrant consideration. First, graphical aids in
the form of network diagrams and forest plots
are typically provided for network meta-analyses.
However, our analysis consisted of upwards
45-treatment nodes when the network was stratified
by dose, mode of administration, and combination
therapies. The inclusion of evidence structures with
a large number of nodes (>20) makes presentation
of network diagrams unwieldy. Similarly, presenta-
tion of forest plots or tables with all comparisons
becomes challenging given the number of treatments
and potential comparisons. As such, we provide
tables which concisely report the main findings
from them in tabular form compared with placebo
(Table 3). We also report absolute probability of
each comparison.
CONCLUSIONS
Triptans were found to be efficacious for the
treatment of acute migraine. Forty-three to 76% of
12232 July/August 2015
patients experience pain relief at 2 hours when using
SD triptan tablets.Most triptans were associated with
equal or more favorable results than NSAIDs, ASA,
acetaminophen, and more favorable results than
ergots. Use of triptans in combination with aspirin or
acetaminophen, or using different modes of adminis-
tration such as injection, was associated with slightly
better results than SD triptan tablets.
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SUPPORTING INFORMATION
Additional Supporting Informationmay be found in
the online version of this article at the publisher’s
website:
Appendix S1.—Search strategy.
Appendix S2.—Included studies.
Appendix S3.—Assessment of inconsistency.
Appendix S4.—Comparisons among standard dose
triptans.
Appendix S5.—Adjustment for control group response
rate.
Appendix S6.—Number of patients and studies for each
outcome.
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